Stockreport

BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash [Reuters]

Affimed N.V.  (AFMD) 
Last affimed n.v. earnings: 11/19 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: affimed.com/investor-relations.php
PDF BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash | Reuters Reuters Staff 1 Min Read Dec 11 (Reuters) - Affimed Nv: * Affime [Read more]